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Dicamphanoyl khellactone (DCK) is a coumarin derivative that can potently inhibit HIV-1 replication. DCK does not inhibit RNA-
dependent DNA synthesis. However, an HIV reverse transcriptase (RT) inhibitor-resistant strain, HIV-1/RTMDR1, is resistant to DCK. Thus,
it is possible that HIV-1 RT is the target of DCK. To test this possibility, DCK-resistant viruses were selected in the presence of DCK. Our
results indicate that a single amino acid mutation, E138K in HIV-1 RT, is sufficient to confer DCK resistance. Interestingly, a DCK
derivative, 3VR,4VR-Di-O-(-)-camphanoyl-2-ethyl-2V,2V-dimethyldihydropyrano[2,3-f]chromone (DCP8), is effective against HIV-1/
RTMDR1. However, the DCK-escape virus carrying the E138K mutation remains resistant to DCP8. Since DCK did not inhibit the
RNA-dependent DNA polymerase activity of HIV-1 RT when using poly-rA or poly-rC as template, we evaluated the effect of DCK on the
DNA-dependent DNA polymerase activity of HIV-1 RT. Our results indicate that DCK can inhibit the DNA-dependent DNA polymerase
activity of HIV-1 RT. In conclusion, DCK is a unique HIV-1 RT inhibitor that inhibits the DNA-dependent DNA polymerase activity. In
contrast, DCK did not significantly affect the RNA-dependent DNA polymerase activity when poly-rA or poly-rC was used as templates. An
E138K mutation in the non-nucleoside RT inhibitors (NNRTIs) binding pocket of HIV-1 RT confers resistance to DCK and its chromone
derivative, DCP8.
D 2004 Elsevier Inc. All rights reserved.
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Since the AIDS pandemic began in the early 1980s,
many efforts have been made to search for effective anti-
HIV-1 drugs. As a result, numerous compounds were found
to have anti-HIV activity. Many of the anti-HIV-1 agents
targeting HIV-1 reverse transcriptase, protease, and gp41
have been used for AIDS therapy. Highly active antire-
troviral therapy (HAART), which combines both HIV-1
reverse transcriptase and protease inhibitors, has been
effective in controlling the viral load in HIV-1-infected
individuals. Although HAART can effectively control
plasma viremia, the virus is suppressed rather than0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 Contribute equally to the study.eradicated (Chun et al., 1997). In addition, several draw-
backs, such as the emergence of drug resistance and side
effects associated with the antiretroviral agents, compromise
many HAART regimens. Therefore, new anti-HIV com-
pounds with unique mechanisms of action are needed to
further improve HAART.
DCK is one of the coumarin derivatives that exhibit
potent anti-HIV activity (Huang et al., 1994). The chemical
structure and mechanism of action of DCK are different
from the drugs currently used in AIDS therapy. The
structure of DCK is illustrated in Fig. 1. DCK was shown
to inhibit HIV-1 at sub-micro molarity concentrations. Due
to the potent anti-HIV activity, many DCK derivatives were
synthesized and were shown to have improved anti-HIV
activity (Xie et al., 1999; Yu et al., 2003). Although DCK is
a potent inhibitor for many HIV-1 isolates, including
primary isolates, the compound is ineffective against an05) 623–628
Fig. 1. Chemical structure of DCK, DCP8, Calanolide A, and TSAO-T.
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NNRTIs (Yu et al., 2004). In order to improve the drug-
resistant profile, a series of compounds with structural
modifications on the khellactone ring of DCK was
synthesized and shown to be effective against the multi-
ple-RT inhibitor-resistant strain (Yu et al., 2004). The
resistance of the pre-existing multiple-RT inhibitor-resistant
strain to DCK suggests that HIV-1 RT might be the target of
the compound. DCK is inactive in an assay that primarily
detects the RNA-dependent DNA polymerase activity of
HIV-1 RT (Huang et al., 1994). DCK appears to inhibit
HIV-1 at a step post-HIV-1 entry, but before integration of
HIV-1 DNA into host chromosomes.
In this study, we have evaluated the activity of DCK
against HIV-1 strains that are resistant to multiple RT
inhibitors and protease inhibitors. We also selected DCK-
resistant mutants and analyzed the genotypes of the DCK
escape mutants. An E138K mutation in the HIV-1 RT is
responsible for the drug resistance. Similar to the reverse
transcriptases in other retroviruses, HIV-1 RT possesses
RNA-dependent DNA polymerase and DNA-dependent
DNA polymerase activities. Unlike other RT inhibitors,
DCK appears to inhibit the DNA-dependent DNA polymer-
ase activity without affecting the RNA-dependent DNA
polymerase activity of HIV-1 reverse transcriptase.Fig. 2. A multiple HIV-1 RT inhibitor-resistant strain is resistant to DCK.Results
HIV-1 resistant to multiple RT inhibitors is less sensitive to
DCK
In an effort to determine whether DCK can inhibit pre-
existing drug-resistant strains, we have tested the anti-HIV
activity of DCK against HIV-1/RTMDR1 and HIV-1/
PRMDR. HIV-1/RTMDR1 contains four mutations,
M41L, L74V, V106A, and T215Y, in HIV-1 RT rendering
the virus resistant to multiple HIV-1 RT inhibitors, including
nucleoside analogs and NNRTIs (Larder et al., 1993). HIV-
1/PRMDR, containing mutations M46I, L63P, V82T, and
I84V in HIV-1 protease, is resistant to multiple protease
inhibitors (Condra et al., 1995). These two drug-resistantstrains and HXB-2, a T-cell line adapted HIV-1 molecular
clone, were tested for their sensitivity to DCK. HXB-2 is
very sensitive to DCK (Fig. 2). The concentration of DCK
required to inhibit 50% of HXB-2 replication (IC50) is 90
nM. The sensitivity of HIV-1/PRMDR to DCK is com-
parable to that of HXB-2. In contrast, HIV-1/RTMDR1 is
approximately 2 logs less sensitive to DCK (Fig. 2). Since
HIV-1/RTMDR1 is a drug-resistant strain constructed in the
genetic background of HXB-2, these results strongly
suggest that HIV-1 RT might be the target of DCK.
An E138K mutation in HIV-1 RT is responsible for DCK
resistance
HIV-1/RTMDR1 has four mutations at amino acid
residues M41L, L74V, V106A, and T215Y of HIV-1 RT
that are responsible for its drug resistance to multiple HIV
RT inhibitors (Larder et al., 1993). These mutations did not
arise from exposure to DCK. In order to gain insight into the
interaction between DCK and its target, drug escape mutants
were selected by growing NL4-3 virus in the presence of
escalating doses of DCK. The drug-resistant mutants were
approximately 2 logs less sensitive to DCK. Sequence
analysis of the DCK escape variants revealed two mutations,
E138K and G550K, in the HIV-1 RT (Fig. 3A). These two
mutations were re-introduced into the wild type NL4-3
molecular clones using site-directed mutagenesis and were
analyzed for their role in DCK resistance. The two viruses
Fig. 3. (A). Changes in amino acid residues in the HIV-1 RT of DCK escape
variants. (B). An E138K mutation confers DCK-resistant phenotype.
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G550K. The G550K mutation did not significantly affect
DCK sensitivity. On the other hand, the E138K mutation
was fully responsible for the resistance to DCK (Fig. 3B).
The E138K mutation in the RT of NL4-3 resulted in a
greater than 100-fold decrease in DCK sensitivity. This
result suggests that E138 of HIV-1 RT plays a key role in the
anti-HIV activity of DCK.
DCP8 is effective against HIV-1/RTMDR1, but not
NL4-3/E138K
DCP8 is one of DCK derivatives designed to improve the
drug-resistant profile of DCK (Yu et al., 2004). The major
difference between DCK and DCP8 is at the khellactone
ring of the molecule (Fig. 1). DCP8 is the most potent
chromone derivative against HIV-1/RTMDR1. Although
HIV-1/RTMDR1 is resistant to DCK, the virus is sensitive
to DCP8 (Fig. 4). The IC50s of DCK and DCP8 againstFig. 4. DCP8 is effective against HIV-1/RTMDR1, but not NL4-3/E138K.HIV-1/RTMDR1 are 8 and 0.06 AM, respectively. Thus, a
structural change on the khellactone ring can overcome the
DCK resistance of HIV-1/RTMDR1. However, the DCK-
resistant mutant, NL4-3/E138K, remains resistant to DCP8
(Fig. 4). These results strengthen the notion that the aminoFig. 5. DCK inhibits the DNA-dependent DNA polymerase activity of HIV-
1 RT. NL4-3 lysate in 1% Triton X-100 was used as HIV-1 RT in the assays.
(A) Poly-dA (Poly-dA/DCK) was used as templates to replace poly rA
(Poly-rA/DCK) in the HIV-1 RT assays to detect the DNA-dependent DNA
polymerase activity. (B) Poly-dC (Poly-dC/DCK) was used as templates to
replace poly-rC (Poly-rC/DCK) in the HIV-1 RT assays to detect DNA-
dependent DNA synthesis, using poly-dC/oligo-dG as template/primer. (C)
M13mp18 plus strand DNAwas used as templates. The primer used in the
assay is described in Materials and methods. Each data point represents the
average of two duplicated experiments.
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HIV-1 activity of DCK and DCP8. Further structural
changes on DCK or DCP8 are needed to improve the
anti-HIV-1 activity against NL4-3/E138K.
DCK inhibits DNA-dependent DNA polymerase activity of
HIV-1 RT
We have previously shown that DCK does not inhibit
HIV-1 RT in an assay used primarily to detect the RNA-
dependent DNA polymerase activity (Huang et al., 1994).
However, the drug-resistant studies described above
strongly suggest that HIV-1 RT is the target of DCK. This
raises the possibility that DCK interacts with HIV-1 RT in a
unique way by inhibiting the DNA-dependent DNA
polymerase activity without affecting the RNA-dependent
DNA polymerase activity of HIV-1 RT. To test this
possibility, we used DNA to replace the RNA templates to
detect the DNA-dependent DNA polymerase activity of
HIV-1 RT. The known DNA chain terminators, ddTTP and
ddGTP, were used as positive controls for the HIV-1 RT
assay. In agreement with previous report (Huang et al.,
1994), DCK did not inhibit HIV-1 RT activity when poly-rA
or poly-rC was used as templates (Figs. 5A and B). In
contrast, DCK can inhibit the DNA-dependent DNA
polymerase activity of HIV-1 RT when poly-dA or poly-
dC was used as templates (Figs. 5A and B). Unlike the
heteropolymeric nature of provial DNA, poly-dA and poly-
dC are homopolymeric templates. To determine whether the
inhibitory activity of DCK can be observed using hetero-
polymeric templates, we used M13mp18 plus strand DNA
as templates in the HIV-1 RT assay. Both ddTTP and DCK
inhibited the DNA-dependent DNA synthesis of HIV-1 RT
when M13mp18 was used as templates (Fig. 5C). The
inhibitory activity of DCK and ddTTP is approximately 3-
fold and 10-fold, respectively, less potent when compared
with assays in which poly-dA or poly-rA was used as
templates (Fig. 5A). Although the DCK concentration
required to inhibit the DNA-dependent DNA polymerase
activity is higher than that required to inhibit HIV-1
replication, the data support the notion that HIV-1 RT is
the target of DCK.Discussion
HIV-1 RT inhibitors, nucleoside analogs, or non-nucleo-
side analogs are able to inhibit RNA-dependent DNA
polymerase activity. DCK appears to be able to inhibit the
HIV-1 RT without significant effect on RNA-dependent
DNA synthesis when poly-rA or poly-rC was used as
templates. The unique mechanism of action might allow
DCK, or its derivatives, to complement with other anti-
HIV-1 agents.
Among all of the known HIV-1 RT inhibitors,
Calanolide A and its derivatives share some structuralsimilarity to DCK (Fig. 1). Like other HIV-1 RT
inhibitors, Calanolide A inhibits HIV-1 reverse transcrip-
tion (Buckheit et al., 1999). Calanolide A-resistant viruses
carry T139I, L100I, Y188H, or L187F mutations in the
RT (Buckheit et al., 1999). The proximity of T139 and
E138 in HIV-1 RT suggests that Calanolide A and DCK
binding sites are likely to be in close proximity. The
E138K mutation is not unique to the DCK-resistant virus.
The identical mutation, E138K, was found to confer drug
resistance to the HIV-1 RT inhibitor, [2V,5V-Bis-O-(tert-
butyldimethylsilyl)- h-d-ribofuranosyl]-3V-spiro-5V-(4’-
amino-1’,2V-oxathiole-2V,2V-dioxide)thymine (TSAO-T)
(Balzarini et al., 1993; Jonckheere et al., 1994). The
chemical structure of TSAO-T is illustrated in Fig. 1.
There is no obvious structural similarity between DCK
and TSAO-T. E138 is one of the amino acid residues
located in a well-defined binding pocket for NNRTIs
(Esnouf et al., 1997; Kohlstaedt et al., 1992). Although
TSAO-T is structurally distinct from both DCK and
Calanolide A (Fig. 1), it is possible that the interactive
sites of DCK, DCP8, Calanolide A, and TSAO-T are in
close proximity. It would be of interest to determine
whether there is a cross resistance among these four anti-
HIV-1 RT inhibitors.
Both NL4-3/E138K and HIV-1/RTMDR1 are highly
resistant to DCK. One of the four mutations, V106A, in the
RT of HIV-1/RTMDR1 is responsible for the resistance to
multiple NNRTIs (Brenner et al., 2003; Larder, 1992).
Similar to E138, V106 is one of the key amino acids in the
NNRTI binding pocket of HIV-1 RT. Thus, the NNRTI
binding pocket is a key determinant for DCK sensitivity. It
is interesting that the DCK derivative, DCP8, is able to
overcome the drug resistance derived from the V106A
mutation, but not the E138K mutation in the RT. It should
be noted that E138 in the NNRTI binding pocket is located
in the p51 subunit of the p51/p66 HIV-1 RT heterodimer.
Other key amino acids residues, such as V106A, in the
NNRTI binding pocket are primarily located in the p66
subunit (Esnouf et al., 1997). Therefore, it is possible that
the primary interactive site for DCK and DCP8 is in the p51
subunit of HIV-1 RT.
Why DCK appears to inhibit DNA-dependent DNA
polymerase activity without affecting the RNA-dependent
DNA polymerase activity? One possibility is that DCK
binds to a site essential for the interaction between HIV-1
RT and DNA template but not RNA template. Alterna-
tively, DCK could bind to the p51 subunit and interfere
with second strand transfer before (+) DNA strand
elongation. It is also possible that DCK impedes the
DNA strand displacement at a late stage of viral DNA
replication. DNA strand displacement appears to be
required for DNA-dependent DNA synthesis during viral
replication (Amacker et al., 1995). Due to its unique mode
of action, DCK and its derivatives could be used to
functionally dissect HIV-1 RT and might have the potential
to be clinically useful.
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Viruses
HIV-1/RTMDR1, an HIV-1 mutant resistant to multiple
RT inhibitors (Larder et al., 1993), and HIV-1/PRMDR, an
HIV-1 strain resistant to multiple protease inhibitors
(Condra et al., 1995), were obtained from the NIH AIDS
Research and Reference Reagent Program. HXB-2 is a
molecular clone derived from HIVLAV (Ratner et al., 1987).
NL4-3 is a chimeric molecular clone derived from NY5 and
HIVLAV (Adachi et al., 1986).
Selection of DCK-resistant viruses
Selection of DCK-resistant NL4-3 variants was carried
out using MT4 cells. The drug-resistant mutants were
generated using escalating concentrations of DCK starting
at a concentration that inhibits 95% of HIV-1 replication
as previously described (Holz-Smith et al., 2001; Yuan et
al., 2004). Viral replication was monitored by measuring
p24 level in the culture supernatants. The HIV-1 RT gene
of the selected DCK-resistant variants was determined
using an automated DNA sequencer (Bio-Synthesis,
Lewisville, TX).
Anti-HIV assay
A modified HIV-1 infectivity assay previously described
was used in the experiments (Zhu et al., 2001). A diluted
HIV-1 stock at a multiplicity of infection (MOI) of 0.001
TCID50/cell was used to infect MT4 cells. Twenty micro-
liters of the virus was incubated with 20 Al of compounds in
RPMI 1640 that contains 10% fetal bovine serum in a 96-
well microtiter plate. Twenty microliters of MT4 cells at 6 
105 cells/ml were added to each well, and the cell culture
was incubated at 37 8C in a humidified CO2 incubator. Two
days after infection, fresh media (180 Al) containing
appropriate concentrations of the compounds were added
to each well. On day 4 post-infection, supernatant samples
were harvested and assayed for p24 using an ELISA kit
from ZeptoMetrix Corporation, Buffalo, NY.
HIV RT assay
HIV-1 RT activity was determined by modifying a
previously published methods (Goff et al., 1981; Willey et
al., 1988). Briefly, HIV-1 NL4-3 culture supernatants were
treated with 1% (vol/vol) Triton X-100. A 10 Al sample of
each viral lysate was mixed with 50 Al of a reaction
cocktail containing 50mMTris–HCl (pH 7.8), 75mMKCl, 2
mM DTT, 5 mM MgCl2, 5 Ag/ml Poly rA, 1.5 Ag/ml Oligo
dT12–18, 0.1 AM dTTP, 0.05% NP-40, and 10 ACi/ml 32P-
TTP. The reaction mixtures were incubated at 37 8C for 90
min. Aliquots (50 Al) of reaction mixtures were spotted onto
DE-81 paper (Whatman) in a sample filtration manifold(Schleicher and Schuell) and washed three times with 2 
SSC (0.3M NaCl, 0.03M NaCitrate). Radioactivity was
quantified with a Packard Matrix 9600 Direct Beta Counter.
The reaction cocktail was modified when M13mp18 plus
strand DNA (Sigma-Aldrich, St. Louis, MO) was used as
template. In addition to the template, an oligonucleotide
(5VGGCCAGTGCCAAGC-3V) complementary to the imme-
diate down stream of the polylinker region of M13mp18 and
dNTPs (a mixture of four nucleotides) were used to replace
Oligo dT12–18 and dTTP, respectively.
Mutagenesis
A quick exchange DNA mutagenesis procedure was used
to introduce desired mutations at specific sites (Holz-Smith
et al., 2001; Yuan et al., 2004). A pair of primers, 5V-GTA
TAA ACA ATA AGA CAC CAG GG-3V and 5V-CCC TGG
TGT CTTATT GTT TATAC-3V, were used to introduce the
E138K mutation into NL4-3 virus. The detailed protocol is
described in the brochure provided by the manufacturer,
Strategene. The sequences of the desired mutants were
confirmed by DNA sequencing.Acknowledgments
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